

FETAL AKINESIA PANEL DG-4.2.0 (103 GENES)

| <i>Gene</i> | <i>Twist X2 covered 10x</i> | <i>Twist X2 covered 20x</i> | <i>srWGS covered 10x</i> | <i>srWGS covered 15x</i> | <i>srWGS covered 20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|-----------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|--|
| ACTA1 | 100% | 100% | 100% | 99.8% | 97.2% | Congenital myopathy 2B, severe infantile, autosomal recessive, 620265;?Myopathy, scapulohumeroperonea I, 616852;Congenital myopathy 2C, severe infantile, autosomal dominant, 620278;Congenital myopathy 2A, typical, autosomal dominant, 161800 |
| ADAMTS15 | 100% | 100% | 100% | 100% | 99.1% | Arthrogryposis, distal, type 12, 620545 |
| ADCY6 | 100% | 100% | 100% | 100% | 99.4% | Lethal congenital contracture syndrome 8, 616287 |
| ADGRG6 | 100% | 100% | 100% | 100% | 99.6% | Lethal congenital contracture syndrome 9, 616503 |
| ALG3 | 100% | 100% | 100% | 100% | 98.9% | Congenital disorder of glycosylation, type Id, 601110 |

| | | | | | | |
|--------|-------|-------|------|------|-------|--|
| ASCC1 | 86.6% | 86.6% | 100% | 100% | 99.3% | Spinal muscular atrophy with congenital bone fractures 2, 616867;Barrett esophagus/esophageal adenocarcinoma, 614266 |
| ATP1A2 | 100% | 100% | 100% | 100% | 98.9% | Developmental and epileptic encephalopathy 98, 619605;Fetal akinesia, respiratory insufficiency, microcephaly, polymicrogyria, and dysmorphic facies, 619602;Alternating hemiplegia of childhood 1, 104290;Migraine, familial basilar, 602481;Migraine, familial hemiplegic, 2, 602481 |
| BICD2 | 100% | 100% | 100% | 100% | 99.5% | Spinal muscular atrophy, lower extremity-predominant, 2B, autosomal dominant, 618291;Spinal muscular atrophy, lower extremity-predominant, 2A, autosomal dominant, 615290 |

| | | | | | | |
|---------|------|-------|------|-------|-------|--|
| BIN1 | 100% | 100% | 100% | 99.8% | 98.8% | Centronuclear myopathy 2, 255200 |
| BLTP1 | 100% | 100% | 100% | 100% | 99.4% | Alkuraya-Kucinskas syndrome, 617822 |
| CACNA1S | 100% | 100% | 100% | 100% | 99.1% | {Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580;Congenital myopathy 18 due to dihydropyridine receptor defect, 620246;Hypokalemic periodic paralysis, type 1, 170400;{Malignant hyperthermia susceptibility 5}, 601887 |
| CHAT | 100% | 99.9% | 100% | 100% | 99.3% | Myasthenic syndrome, congenital, 6, presynaptic, 254210 |
| CHRNA1 | 100% | 100% | 100% | 100% | 99.2% | Myasthenic syndrome, congenital, 1B, fast-channel, 608930;Myasthenic syndrome, congenital, 1A, slow-channel, 601462;Multiple pterygium syndrome, lethal type, 253290 |

| | | | | | | |
|---------|------|------|------|-------|-------|--|
| CHRNE | 100% | 100% | 100% | 100% | 98.9% | Myasthenic syndrome, congenital, 4A, slow-channel, 605809;Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931;Myasthenic syndrome, congenital, 4B, fast-channel, 616324 |
| CHRNA3 | 100% | 100% | 100% | 100% | 99% | Multiple pterygium syndrome, lethal type, 253290;Escobar syndrome, 265000 |
| CHST14 | 100% | 100% | 100% | 99.8% | 97.5% | Ehlers-Danlos syndrome, musculocontractural type 1, 601776 |
| CNTNAP1 | 100% | 100% | 100% | 99.9% | 98.7% | Lethal congenital contracture syndrome 7, 616286;Hypomyelinating neuropathy, congenital, 3, 618186 |
| COL12A1 | 100% | 100% | 100% | 100% | 99.6% | Bethlem myopathy 2, 616471;?Ullrich congenital muscular dystrophy 2, 616470 |

| | | | | | | |
|--------|-------|-------|------|-------|-------|---|
| COL6A1 | 100% | 100% | 100% | 99.8% | 98.8% | Ullrich congenital muscular dystrophy 1A, 254090;Bethlem myopathy 1A, 158810 |
| COL6A2 | 100% | 100% | 100% | 100% | 98.9% | ?Myosclerosis, congenital, 255600;Ullrich congenital muscular dystrophy 1B, 620727;Bethlem myopathy 1B, 620725 |
| COL6A3 | 100% | 100% | 100% | 99.9% | 99.4% | Bethlem myopathy 1C, 620726;Ullrich congenital muscular dystrophy 1C, 620728;Dystonia 27, 616411 |
| COX15 | 100% | 100% | 100% | 100% | 99.1% | Mitochondrial complex IV deficiency, nuclear type 6, 615119 |
| CRPPA | 100% | 100% | 100% | 100% | 99.6% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 |
| DHCR24 | 100% | 100% | 100% | 99.8% | 98.7% | Desmosterolosis, 602398 |
| DHCR7 | 96.2% | 96.2% | 100% | 99.9% | 99.2% | Smith-Lemli-Opitz syndrome, 270400 |

| | | | | | | |
|-------|------|------|------|-------|-------|--|
| DNM2 | 100% | 100% | 100% | 100% | 99.2% | Centronuclear myopathy 1, 160150;Charcot-Marie-Tooth disease, axonal type 2M, 606482;Charcot-Marie-Tooth disease, dominant intermediate B, 606482;Lethal congenital contracture syndrome 5, 615368 |
| DOK7 | 100% | 100% | 100% | 100% | 98.5% | Fetal akinesia deformation sequence 3, 618389;Myasthenic syndrome, congenital, 10, 254300 |
| ECEL1 | 100% | 100% | 100% | 99.9% | 98.8% | Arthrogryposis, distal, type 5D, 615065 |
| EGR2 | 100% | 100% | 100% | 100% | 98.8% | Dejerine-Sottas disease, 145900;Charcot-Marie-Tooth disease, type 1D, 607678;Hypomyelinating neuropathy, congenital, 1, 605253 |

| | | | | | | |
|-------|------|------|------|-------|-------|---|
| ERBB3 | 100% | 100% | 100% | 99.9% | 98.3% | ?Lethal congenital contractural syndrome 2, 607598;{?Erythroleukemia, familial, susceptibility to}, 133180;Visceral neuropathy, familial, 1, autosomal recessive, 243180 |
| ERCC5 | 100% | 100% | 100% | 99.9% | 99.3% | Xeroderma pigmentosum, group G, 278780;Cerebrooculofacioskeletal syndrome 3, 616570;Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 |
| ERCC6 | 100% | 100% | 100% | 100% | 99.3% | UV-sensitive syndrome 1, 600630;Cerebrooculofacioskeletal syndrome 1, 214150;?De Sanctis-Cacchione syndrome, 278800;Cockayne syndrome, type B, 133540;{Macular degeneration, age-related, susceptibility to, 5}, 613761;Premature ovarian failure 11, 616946;{Lung cancer, susceptibility to}, 211980 |

| | | | | | | |
|------|-------|-------|------|-------|-------|---|
| FBN2 | 99.2% | 99.2% | 100% | 100% | 99.4% | Macular degeneration, early-onset, 616118;Contractural arachnodactyly, congenital, 121050 |
| FKRP | 100% | 100% | 100% | 99.9% | 98.6% | Muscular dystrophy-dystroglycanopathy (congenital with or without impaired intellectual development), type B, 5, 606612;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 |
| FLNC | 100% | 100% | 100% | 100% | 99% | Cardiomyopathy, familial hypertrophic, 26, 617047;Arrhythmogenic right ventricular dysplasia, familial, 617047;Cardiomyopathy, familial restrictive 5, 617047;Myopathy, distal, 4, 614065;Myopathy, myofibrillar, 5, 609524 |

| | | | | | | |
|--------|------|------|------|-------|-------|--|
| FLVCR2 | 100% | 100% | 100% | 99.9% | 99.4% | Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 |
| GBA1 | 100% | 100% | 100% | 100% | 99.3% | {Lewy body dementia, susceptibility to}, 127750;Gaucher disease, type II, 230900;Gaucher disease, type IIIC, 231005;Gaucher disease, type III, 231000;Gaucher disease, type I, 230800;Gaucher disease, perinatal lethal, 608013;{Parkinson disease, late-onset, susceptibility to}, 168600 |
| GBE1 | 100% | 100% | 100% | 100% | 99.5% | Glycogen storage disease IV, 232500;Polyglucosan body disease, adult form, 263570 |
| GLDN | 100% | 100% | 100% | 100% | 99.4% | Lethal congenital contracture syndrome 11, 617194 |

| | | | | | | |
|---------|------|------|------|------|-------|---|
| GLE1 | 100% | 100% | 100% | 100% | 99.1% | Lethal congenital contracture syndrome 1, 253310; Congenital arthrogryposis with anterior horn cell disease, 611890 |
| GMPPB | 100% | 100% | 100% | 100% | 99.2% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352; Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 14, 615351; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 |
| IGHMBP2 | 100% | 100% | 100% | 100% | 99.6% | Charcot-Marie-Tooth disease, axonal, type 2S, 616155; Neuronopathy, distal hereditary motor, autosomal recessive 1, 604320 |

| | | | | | | |
|-----------|------|------|------|-------|-------|---|
| KIDINS220 | 100% | 100% | 100% | 100% | 99.5% | Spastic paraplegia, intellectual disability, nystagmus, and obesity, 617296;Ventriculomegaly and arthrogryposis, 619501 |
| KIF5C | 100% | 100% | 100% | 99.9% | 99.4% | Cortical dysplasia, complex, with other brain malformations 2, 615282 |
| KLHL40 | 100% | 100% | 100% | 99.9% | 98.8% | Nemaline myopathy 8, autosomal recessive, 615348 |
| KLHL41 | 100% | 100% | 100% | 100% | 99.8% | Nemaline myopathy 9, 615731 |
| LGI4 | 100% | 100% | 100% | 99.9% | 98.4% | Arthrogryposis multiplex congenita 1, neurogenic, with myelin defect, 617468 |

| | | | | | | |
|--------|------|------|-------|-------|-------|---|
| LMNA | 100% | 100% | 100% | 99.9% | 99.1% | Mandibuloacral dysplasia, 248370;Heart-hand syndrome, Slovenian type, 610140;Cardiomyopathy, dilated, 1A, 115200;Emery-Dreifuss muscular dystrophy 3, autosomal recessive, 616516;Restrictive dermopathy 2, 619793;Charcot-Marie-Tooth disease, type 2B1, 605588;Emery-Dreifuss muscular dystrophy 2, autosomal dominant, 181350;Hutchinson-Gilford progeria, 176670;Lipodystrophy, familial partial, type 2, 151660;Muscular dystrophy, congenital, 613205;Malouf syndrome, 212112 |
| LMOD3 | 100% | 100% | 99.9% | 99.5% | 97.4% | Nemaline myopathy 10, 616165 |
| MAGEL2 | 100% | 100% | 100% | 99.9% | 98.7% | Schaaf-Yang syndrome, 615547 |

| | | | | | | |
|--------|------|------|-------|-------|-------|--|
| MEGF10 | 100% | 100% | 100% | 100% | 99.2% | Congenital myopathy 10A, severe variant, 614399; Congenital myopathy 10B, mild variant, 620249 |
| MPZ | 100% | 100% | 100% | 100% | 98.6% | Charcot-Marie-Tooth disease, type 2I, 607677; Dejerine-Sottas disease, 145900; Charcot-Marie-Tooth disease, type 1B, 118200; Roussy-Levy syndrome, 180800; Charcot-Marie-Tooth disease, dominant intermediate D, 607791; Hypomyelinating neuropathy, congenital, 2, 618184; Charcot-Marie-Tooth disease, type 2J, 607736 |
| MTM1 | 100% | 100% | 99.4% | 89.9% | 69.2% | Myopathy, centronuclear, X-linked, 310400 |
| MUSK | 100% | 100% | 100% | 100% | 98.9% | Fetal akinesia deformation sequence 1, 208150; Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 |

| | | | | | | |
|--------|------|-------|------|-------|-------|--|
| MYBPC1 | 100% | 100% | 100% | 100% | 99.5% | Congenital myopathy 16, 618524;Lethal congenital contracture syndrome 4, 614915;Arthrogryposis, distal, type 1B, 614335 |
| MYCN | 100% | 99.4% | 100% | 99.8% | 98.6% | Feingold syndrome 1, 164280;Megalocephaly-polydactyly syndrome, 620748 |
| MYH3 | 100% | 100% | 100% | 100% | 99.3% | Contractures, pterygia, and spondylocarpostarsal fusion syndrome 1A, 178110;Contractures, pterygia, and spondylocarpotarsal fusion syndrome 1B, 618469;Arthrogryposis, distal, type 2B3 (Sheldon-Hall), 618436;Arthrogryposis, distal, type 2A (Freeman-Sheldon), 193700 |
| MYH8 | 100% | 100% | 100% | 100% | 99.5% | Carney complex variant, 608837;Trismus-pseudocamptodactyly syndrome, 158300 |
| MYL11 | 100% | 100% | 100% | 99.8% | 98.3% | Arthrogryposis, distal, type 1C, 619110 |

| | | | | | | |
|-------|-------|-------|-------|-------|-------|--|
| MYMK | 100% | 100% | 100% | 99.9% | 98.6% | Carey-Fineman-Ziter syndrome, 254940 |
| MYOD1 | 100% | 100% | 100% | 100% | 98.5% | Congenital myopathy 17, 618975 |
| NEB | 99.9% | 99.8% | 99.7% | 99.2% | 98% | Nemaline myopathy 2, autosomal recessive, 256030;Arthrogryposis multiplex congenita 6, 619334 |
| NEK9 | 100% | 100% | 100% | 99.9% | 99.5% | ?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262;Nevus comedonicus, somatic, 617025;Lethal congenital contracture syndrome 10, 617022 |
| NUP88 | 93.4% | 93.4% | 100% | 100% | 99.5% | Fetal akinesia deformation sequence 4, 618393 |
| PHGDH | 100% | 100% | 100% | 100% | 99.4% | Neu-Laxova syndrome 1, 256520;Phosphoglycerate dehydrogenase deficiency, 601815 |

| | | | | | | |
|---------|------|------|------|-------|-------|--|
| PIEZO2 | 100% | 100% | 100% | 99.9% | 99.1% | Arthrogryposis, distal, type 5, 108145;Arthrogryposis, distal, with impaired proprioception and touch, 617146;Arthrogryposis, distal, type 3, 114300;?Marden-Walker syndrome, 248700 |
| PIP5K1C | 100% | 100% | 100% | 100% | 98.8% | Lethal congenital contractural syndrome 3, 611369 |
| PLOD1 | 100% | 100% | 100% | 99.8% | 97.7% | Ehlers-Danlos syndrome, kyphoscoliotic type, 1, 225400 |
| PSAT1 | 100% | 100% | 100% | 100% | 99.8% | Neu-Laxova syndrome 2, 616038;Phosphoserine aminotransferase deficiency, 610992 |
| PTRH2 | 100% | 100% | 100% | 100% | 99.6% | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 |

| | | | | | | |
|-------|-------|-------|------|-------|-------|--|
| RAPSN | 100% | 100% | 100% | 99.8% | 98.3% | Fetal akinesia deformation sequence 2, 618388;Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 |
| RIPK4 | 100% | 99.9% | 100% | 99.9% | 99.3% | CHAND syndrome, 214350;Popliteal pterygium syndrome, Bartsocas-Papas type 1, 263650 |
| RYR1 | 99.9% | 99.6% | 100% | 99.9% | 98% | Congenital myopathy 1B, autosomal recessive, 255320;Congenital myopathy 1A, autosomal dominant, with susceptibility to malignant hyperthermia, 117000;King-Denborough syndrome, 619542;{Malignant hyperthermia susceptibility 1}, 145600 |

| | | | | | | |
|---------|-------|-------|------|-------|-------|---|
| SCN4A | 100% | 100% | 100% | 100% | 98.9% | Paramyotonia congenita, 168300;Hyperkalemic periodic paralysis, 170500;Congenital myopathy 22B, severe fetal, 620369;Hypokalemic periodic paralysis, type 2, 613345;Myotonia congenita, atypical, acetazolamide-responsive, 608390;Myasthenic syndrome, congenital, 16, 614198;Congenital myopathy 22A, classic, 620351 |
| SCYL2 | 100% | 100% | 100% | 100% | 99.5% | Arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum, 618766 |
| SELENON | 90.4% | 86.7% | 100% | 99.8% | 98.3% | Congenital myopathy 3 with rigid spine, 602771 |
| SLC35A3 | 97.6% | 90% | 100% | 100% | 99.4% | Arthrogryposis, impaired intellectual development, and seizures, 615553 |

| | | | | | | |
|--------|------|-------|-------|-------|-------|---|
| SLC5A7 | 100% | 100% | 100% | 99.9% | 98.9% | Neuronopathy, distal hereditary motor, autosomal dominant 7, 158580;Myasthenic syndrome, congenital, 20, presynaptic, 617143 |
| SLC6A9 | 100% | 100% | 100% | 99.9% | 98.6% | Glycine encephalopathy with normal serum glycine, 617301 |
| SMPD4 | 100% | 100% | 100% | 99.9% | 99.2% | Neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 |
| SRPK3 | 100% | 99.3% | 98.4% | 86.4% | 66% | Intellectual developmental disorder, X-linked 114, 301134 |
| STAC3 | 100% | 100% | 100% | 100% | 99.2% | Congenital myopathy 13, 255995 |
| SYNE1 | 100% | 100% | 100% | 100% | 99.5% | Arthrogryposis multiplex congenita 3, myogenic type, 618484;Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998;Spinocerebellar ataxia, autosomal recessive 8, 610743 |

| | | | | | | |
|-------|-------|-------|------|-------|-------|---|
| TBCD | 91.2% | 90.6% | 100% | 99.9% | 98.5% | Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum, 617193 |
| TNNI2 | 100% | 100% | 100% | 100% | 99.6% | Arthrogryposis, distal, type 2B1, 601680 |
| TNNT3 | 100% | 100% | 100% | 99.9% | 99% | Arthrogryposis, distal, type 2B2, 618435 |
| TOR1A | 93.1% | 90.8% | 100% | 100% | 99.2% | {Dystonia-1, modifier of};Arthrogryposis multiplex congenita 5, 618947;Dystonia-1, torsion, 128100 |
| TPM2 | 100% | 100% | 100% | 99.9% | 98.8% | Arthrogryposis, distal, type 2B4, 108120;Arthrogryposis, distal, type 1A, 108120;Congenital myopathy 23, 609285 |
| TPM3 | 100% | 100% | 100% | 100% | 99% | Congenital myopathy 4A, autosomal dominant, 255310;Congenital myopathy 4B, autosomal recessive, 609284 |

| | | | | | | |
|-------|------|------|------|-------|-------|--|
| TRIP4 | 100% | 100% | 100% | 100% | 99.2% | ?Muscular dystrophy, congenital, Davignon-Chauveau type, 617066;Spinal muscular atrophy with congenital bone fractures 1, 616866 |
| TRPV4 | 100% | 100% | 100% | 99.9% | 98.5% | Neuronopathy, distal hereditary motor, autosomal dominant 8, 600175;Spondylometap hyseal dysplasia, Kozlowski type, 184252;Digital arthropathy-brachydactyly, familial, 606835;[Sodium serum level QTL 1], 613508;SED, Maroteaux type, 184095;Metatropic dysplasia, 156530;Scapuloperone al spinal muscular atrophy, 181405;Hereditary motor and sensory neuropathy, type IIc, 606071;?Avascular necrosis of femoral head, primary, 2, 617383;Parastremmatic dwarfism, 168400;Brachyolmia type 3, 113500 |

| | | | | | | |
|--------|------|-------|-------|-------|-------|---|
| TTN | 100% | 100% | 100% | 99.9% | 99.5% | Muscular dystrophy, limb-girdle, autosomal recessive 10, 608807;Cardiomyopathy, familial hypertrophic, 9, 613765;Congenital myopathy 5 with cardiomyopathy, 611705;Tibial muscular dystrophy, tardive, 600334;Cardiomyopathy, dilated, 1G, 604145;Myopathy, myofibrillar, 9, with early respiratory failure, 603689 |
| TUBA1A | 100% | 100% | 100% | 100% | 99.2% | Lissencephaly 3, 611603 |
| TUBB2B | 100% | 100% | 100% | 100% | 99.2% | Cortical dysplasia, complex, with other brain malformations 7, 610031 |
| UBA1 | 100% | 99.7% | 98.9% | 87.8% | 68% | Spinal muscular atrophy, X-linked 2, infantile, 301830;VEXAS syndrome, somatic, 301054 |
| VAMP1 | 100% | 100% | 100% | 100% | 98.6% | Myasthenic syndrome, congenital, 25, 618323;Spastic ataxia 1, autosomal dominant, 108600 |

| | | | | | | |
|----------|-------|-------|-------|-------|-------|---|
| VIPAS39 | 100% | 100% | 100% | 100% | 99.4% | Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 |
| VPS33B | 100% | 100% | 100% | 99.9% | 98.6% | Keratoderma-ichthyosis-deafness syndrome, autosomal recessive, 620009;Cholestasis, progressive familial intrahepatic, 12, 620010;Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 |
| WDR62 | 98.8% | 98.7% | 100% | 100% | 99.3% | Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 |
| ZC4H2 | 100% | 99.7% | 98.9% | 89.8% | 69.6% | Wieacker-Wolff syndrome, 314580;Wieacker-Wolff syndrome, female-restricted, 301041 |
| ZMPSTE24 | 100% | 100% | 100% | 100% | 99.5% | Mandibuloacral dysplasia with type B lipodystrophy, 608612;Restrictive dermopathy 1, 275210 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. *Nucleic Acids Res.* 2015 Jan 43(Database issue):D1079-85.

TWIST X2 covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using *TWIST X2* chemistry mapped against GRCh38.

TWIST X2 covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using *TWIST X2* chemistry mapped against GRCh38.

srWGS covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.

srWGS covered 15x describes the percentage of a gene's coding sequence that is covered at least 15x when analyzed by WGS mapped against GRCh38.

srWGS covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : November 25th, 2024.

This list is accurate for panel version DG 4.2.0

Ad 1. Blank field signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors